title: Reply to Musher.
authors.affiliation: Department of Immunisation, Hepatitis and Blood Safety, Public Health England, London, United Kingdom Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale, Québec, Canada.
authors.forename: Nicholas
authors.initials: N
authors.lastname: Brousseau
authors.affiliation: Department of Medicine, Griffith University, Southport, Queensland, Australia Institute of Hygiene and Microbiology, University of Würzburg, Germany.
authors.forename: Mary P E
authors.initials: MP
authors.lastname: Slack
authors.affiliation: Department of Immunisation, Hepatitis and Blood Safety, Public Health England, London, United Kingdom.
authors.forename: Pauline
authors.initials: P
authors.lastname: Waight
authors.affiliation: Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, United Kingdom.
authors.forename: Ray
authors.initials: R
authors.lastname: Borrow
authors.affiliation: Department of Immunisation, Hepatitis and Blood Safety, Public Health England, London, United Kingdom.
authors.forename: Shamez N
authors.initials: SN
authors.lastname: Ladhani
mesh_terms: D000907:Antibodies, Bacterial / Q000097:blood*; D005260:Female; D000069443:Heptavalent Pneumococcal Conjugate Vaccine / Q000276:immunology*; D006801:Humans; D008297:Male; D011008:Pneumococcal Infections / Q000276:immunology* / Q000382:microbiology*; D013296:Streptococcus pneumoniae / Q000276:immunology*
chemical_list: D000907:Antibodies, Bacterial; D000069443:Heptavalent Pneumococcal Conjugate Vaccine